KTTA Pasithea Therapeutics Corp
-
Pasithea Therapeutics Reported In-line with Estimates
Friday, August 14, 2026 · 12:00 AM ET
Pasithea Therapeutics (KTTA) reported a loss of $0.16 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.16 per share. The company reported in-line with consensus estimates.
Pasithea Therapeutics Corp. is a biotechnology company. It focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Pasithea Therapeutics Corp. is based in MIAMI BEACH, Fla.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.16)
Earnings Whisper®
—
Consensus Estimate
($0.16)
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—